NAT10-mediated ac4C modification of KDM1B drives osteoarthritis progression through epigenetic suppression of SOX9
Cellular and Molecular Life Sciences · 2025
DOI: 10.1007/s00018-025-05918-z ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular and Molecular Life Sciences, 2025. Verfasst von Shuxiang Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic, Jiangmen Wuyi Hospital of Traditional Chinese Medicine, Jiangmen, Guangdong, China. Hauptthemen laut MEDLINE: Osteoarthritis, SOX9 Transcription Factor, Epigenesis, Genetic, Jumonji Domain-Containing Histone Demethylases. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Histone methylation acts as a crucial regulator of diverse pathophysiological processes in humans. However, the involvement of histone methylation modification enzymes in osteoarthritis (OA) remains poorly characterized. Here, we delineated lysine demethylase 1B (KDM1B) as a nodal epigenetic effector driving OA pathobiology through an integrated strategy that combined data mining, bioinformatics analysis, and experimental validation. Gain-of-function studies revealed that chondrocyte - specific KDM1B overexpression amplified IL-1β-induced chondrocyte injury primarily through the inhibition of SRY-box transcription factor 9 (SOX9). Conversely, KDM1B knockdown inhibited IL-1β-induced chondrocyte damage in vitro and significantly alleviated OA progression in vivo by upregulating SOX9. Mechanistically, NAT10-catalyzed ac4C epitranscriptomic editing to KDM1B mRNA stabilization, leading to its overexpression in osteoarthritic chondrocytes. Elevated KDM1B subsequently binds to the promoter region of the SOX9 and catalyzes the demethylation of H3K4me2 to suppress SOX9 expression in osteoarthritic chondrocytes. Furthermore, our data also demonstrated that chondrocyte-specific NAT10 knockdown attenuated IL-1β-induced chondrocyte injury by modulating the KDM1B/SOX9 axis. Collectively, our findings unveil a novel NAT10/KDM1B/SOX9 regulatory cascade in OA pathogenesis, highlighting the potential of targeting epigenetic regulators to restore chondrocyte function and mitigate OA progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedic, Jiangmen Wuyi Hospital of Traditional Chinese Medicine, Jiangmen, Guangdong, China.
- Department of Orthopaedic, Enping Branch of Jiangmen Wuyi Hospital of Traditional Chinese Medicine, Jiangmen, Guangdong, China.
- Department of Orthopaedic, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China. qiwz@smu.edu.cn.
- Department of Orthopaedic, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China. warriorkof@163.com.
Zitieren
APA
Chen, S., Ou, W., Li, X., Jie, M., Zheng, Y., Situ, J., Liao, Z., Huang, L., Qi, W., & Ni, S. (2025). NAT10-mediated ac4C modification of KDM1B drives osteoarthritis progression through epigenetic suppression of SOX9. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-025-05918-z
Vancouver
Chen S, Ou W, Li X, Jie M, Zheng Y, Situ J, et al. NAT10-mediated ac4C modification of KDM1B drives osteoarthritis progression through epigenetic suppression of SOX9. Cellular and Molecular Life Sciences. 2025. doi:10.1007/s00018-025-05918-z
BibTeX
@article{Chen2025,
author = {Chen, Shuxiang and Ou, Wenhuan and Li, Xiaotao and Jie, Mufu and Zheng, Yi and Situ, Jian and Liao, Zhipeng and Huang, Li and Qi, Weizhong and Ni, Songjia},
title = {NAT10-mediated ac4C modification of KDM1B drives osteoarthritis progression through epigenetic suppression of SOX9},
journal = {Cellular and Molecular Life Sciences},
year = {2025},
doi = {10.1007/s00018-025-05918-z}
}
EUVIMED